Journal of cosmetic dermatology · 2024
Efficacy and Safety of Combination Therapy of Microneedling Radiofrequency, In-Office and Home-Based Topical Cysteamine in Refractory Melasma: A Split Face, Vehicle-Control, Randomized Control Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsai Ya-Wen, Lin Jeng-Hsien, Lai Yi-Jing, Liu Tzu-Li, Ng Chau Yee
Аннотация
BACKGROUND: Refractory melasma remains a challenge in dermatology, necessitating the exploration of innovative treatments.
AIMS: This study aims to evaluate the efficacy and safety of combining radiofrequency microneedling (RFM) with Cysteamine cream, applied both in-office and as a part of a home-care regimen, to treat refractory melasma.
PATIENTS/METHODS: A vehicle-controlled, split-face trial was conducted on 30 Fitzpatrick skin types III and IV participants. Subjects received RFM and Cysteamine serum on one side of the face and RFM with saline on the contralateral side. Additionally, a random half-added Cysteamine cream was applied at home. The modified Melasma Area and Severity Index and VISIA skin analysis were used for assessment.
RESULTS: Significant improvement in melasma severity and skin texture was noted on the sides treated with RFM and Cysteamine, including observable benefits from both in-office and home-based Cysteamine use with minimal adverse effects.
CONCLUSIONS: The combined approach of RFM with Cysteamine provides a promising and safe modality for managing refractory melasma, showing notable improvements.
AIMS: This study aims to evaluate the efficacy and safety of combining radiofrequency microneedling (RFM) with Cysteamine cream, applied both in-office and as a part of a home-care regimen, to treat refractory melasma.
PATIENTS/METHODS: A vehicle-controlled, split-face trial was conducted on 30 Fitzpatrick skin types III and IV participants. Subjects received RFM and Cysteamine serum on one side of the face and RFM with saline on the contralateral side. Additionally, a random half-added Cysteamine cream was applied at home. The modified Melasma Area and Severity Index and VISIA skin analysis were used for assessment.
RESULTS: Significant improvement in melasma severity and skin texture was noted on the sides treated with RFM and Cysteamine, including observable benefits from both in-office and home-based Cysteamine use with minimal adverse effects.
CONCLUSIONS: The combined approach of RFM with Cysteamine provides a promising and safe modality for managing refractory melasma, showing notable improvements.